Boehringer Ingelheim Vetmedica Gmbh

Other

Boehringer Ingelheim Animal Health USA Inc.

Phillip Wayne Hayes

Michael B Roof

Marc Allan Eichmeyer

Merrill Lynn Schaeffer

Gregory Paul Nitzel

Greg Nitzel

Kristina J Hennessy

Eric Martin Vaughn

Jeffrey P Knittel

John Randall Swart

Michael Beck

Karen E Freking

Reid C Phillips

Andres Diaz-Mendez

Laurent Viel

Marc Eichmeyer

Merrill Schaeffer

Mark Eichmeyer

Andrés Diaz-Mendez

Michael Roof

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.

Multivalent PCV2 immunogenic compositions and methods of producing such compositions

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.

Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs

The disclosure provides for immunogenic compositions against Pigeon Fever, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include otherpathogens.

Immunogenic compositions and methods for pigeon fever

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated withinfections.

The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.

West Nile Virus vaccine

The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.

Equine rhinitis vaccine

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2ORF2 protein, and immunogenic compositions comprising PCV2ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2ORF2 protein, or an immunogenic composition comprising PCV2ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.

The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused byand at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least oneantigen, preferably the attenuated, avirulentas provided herewith and one or more further immunologically active components effective for the treatment and/or prophylaxis of infections caused by a further pathogen of cattle.

Growing community of inventors

Maurice, IA, United States of America

Phillip Wayne Hayes